Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 31 | 2022 | 949 | 5.210 |
Why?
|
Prostatic Neoplasms | 13 | 2022 | 262 | 2.890 |
Why?
|
Tamoxifen | 9 | 2016 | 56 | 2.630 |
Why?
|
Cancer Survivors | 4 | 2022 | 83 | 2.350 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2024 | 244 | 2.110 |
Why?
|
Aromatase Inhibitors | 6 | 2016 | 32 | 2.090 |
Why?
|
Survivors | 10 | 2022 | 149 | 1.920 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2017 | 63 | 1.710 |
Why?
|
Humans | 78 | 2024 | 17611 | 1.480 |
Why?
|
Aged | 54 | 2024 | 6095 | 1.470 |
Why?
|
Neoplasms | 3 | 2023 | 438 | 1.410 |
Why?
|
Androgen Antagonists | 5 | 2017 | 17 | 1.400 |
Why?
|
Middle Aged | 55 | 2024 | 7911 | 1.330 |
Why?
|
Cardiovascular Diseases | 6 | 2017 | 598 | 1.190 |
Why?
|
Female | 46 | 2024 | 12608 | 1.110 |
Why?
|
Depressive Disorder | 2 | 2022 | 222 | 1.060 |
Why?
|
Proportional Hazards Models | 13 | 2021 | 709 | 1.050 |
Why?
|
California | 21 | 2023 | 2284 | 1.040 |
Why?
|
Neoplasms, Second Primary | 2 | 2016 | 29 | 0.940 |
Why?
|
CA-125 Antigen | 2 | 2020 | 6 | 0.890 |
Why?
|
Health Maintenance Organizations | 4 | 2017 | 417 | 0.870 |
Why?
|
Membrane Proteins | 2 | 2020 | 38 | 0.870 |
Why?
|
Ovarian Neoplasms | 2 | 2020 | 49 | 0.840 |
Why?
|
Adult | 31 | 2022 | 7598 | 0.830 |
Why?
|
Aged, 80 and over | 20 | 2021 | 1900 | 0.820 |
Why?
|
Neoplasm Staging | 13 | 2016 | 325 | 0.810 |
Why?
|
Paroxetine | 2 | 2015 | 23 | 0.770 |
Why?
|
Male | 38 | 2024 | 10008 | 0.740 |
Why?
|
Risk Factors | 19 | 2021 | 3325 | 0.730 |
Why?
|
Health Services Accessibility | 1 | 2023 | 289 | 0.710 |
Why?
|
Retrospective Studies | 13 | 2023 | 2447 | 0.710 |
Why?
|
Depression | 3 | 2022 | 502 | 0.700 |
Why?
|
Cohort Studies | 20 | 2022 | 2570 | 0.680 |
Why?
|
Insurance, Health | 1 | 2021 | 181 | 0.670 |
Why?
|
Obesity | 4 | 2021 | 837 | 0.660 |
Why?
|
Healthcare Disparities | 1 | 2021 | 201 | 0.630 |
Why?
|
Endometrial Neoplasms | 2 | 2015 | 35 | 0.620 |
Why?
|
Patient Compliance | 3 | 2020 | 298 | 0.610 |
Why?
|
Arrhythmias, Cardiac | 1 | 2017 | 32 | 0.580 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 3 | 0.570 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 2 | 0.570 |
Why?
|
Prognosis | 11 | 2022 | 606 | 0.530 |
Why?
|
Sigmoidoscopy | 2 | 2007 | 65 | 0.530 |
Why?
|
Algorithms | 4 | 2020 | 233 | 0.520 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2015 | 28 | 0.520 |
Why?
|
Pathology Department, Hospital | 1 | 2015 | 3 | 0.500 |
Why?
|
Diphosphonates | 1 | 2016 | 62 | 0.500 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2017 | 14 | 0.500 |
Why?
|
Overweight | 2 | 2021 | 269 | 0.490 |
Why?
|
Medication Adherence | 2 | 2017 | 244 | 0.490 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 40 | 0.480 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2016 | 18 | 0.470 |
Why?
|
Biomarkers, Tumor | 4 | 2020 | 142 | 0.450 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2024 | 56 | 0.420 |
Why?
|
Research Design | 1 | 2015 | 374 | 0.420 |
Why?
|
Arsenic | 4 | 2007 | 5 | 0.420 |
Why?
|
Multivariate Analysis | 4 | 2021 | 568 | 0.410 |
Why?
|
Antidepressive Agents | 2 | 2022 | 155 | 0.410 |
Why?
|
Social Class | 3 | 2023 | 120 | 0.400 |
Why?
|
Follow-Up Studies | 11 | 2024 | 1210 | 0.400 |
Why?
|
Heart Failure | 1 | 2017 | 396 | 0.400 |
Why?
|
Inflammation | 1 | 2012 | 62 | 0.400 |
Why?
|
Neoplasm Grading | 4 | 2017 | 48 | 0.400 |
Why?
|
Sleep Wake Disorders | 1 | 2012 | 37 | 0.400 |
Why?
|
Mass Screening | 2 | 2009 | 661 | 0.390 |
Why?
|
Prostate-Specific Antigen | 3 | 2016 | 75 | 0.390 |
Why?
|
Prospective Studies | 11 | 2024 | 1267 | 0.380 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 108 | 0.380 |
Why?
|
Registries | 7 | 2021 | 471 | 0.370 |
Why?
|
Continental Population Groups | 2 | 2009 | 302 | 0.370 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 4 | 0.360 |
Why?
|
Socioeconomic Factors | 3 | 2023 | 630 | 0.360 |
Why?
|
Body Mass Index | 3 | 2013 | 958 | 0.350 |
Why?
|
Preventive Health Services | 1 | 2012 | 159 | 0.350 |
Why?
|
Cross-Sectional Studies | 10 | 2012 | 1322 | 0.340 |
Why?
|
Risk | 6 | 2020 | 516 | 0.340 |
Why?
|
Electronic Health Records | 1 | 2015 | 681 | 0.340 |
Why?
|
Comorbidity | 4 | 2023 | 594 | 0.330 |
Why?
|
Case-Control Studies | 13 | 2015 | 1115 | 0.330 |
Why?
|
Prostatectomy | 5 | 2016 | 75 | 0.330 |
Why?
|
Incidence | 9 | 2015 | 1255 | 0.320 |
Why?
|
Prostate | 2 | 2022 | 28 | 0.320 |
Why?
|
Managed Care Programs | 1 | 2010 | 325 | 0.300 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2017 | 10 | 0.300 |
Why?
|
Water Supply | 3 | 2007 | 8 | 0.300 |
Why?
|
Environmental Exposure | 4 | 2007 | 116 | 0.300 |
Why?
|
Insurance Carriers | 1 | 2007 | 6 | 0.290 |
Why?
|
Organizations, Nonprofit | 1 | 2007 | 11 | 0.290 |
Why?
|
Practice Patterns, Physicians' | 1 | 2010 | 330 | 0.290 |
Why?
|
Keratosis | 2 | 2004 | 2 | 0.280 |
Why?
|
Salvage Therapy | 2 | 2016 | 17 | 0.280 |
Why?
|
Colorectal Neoplasms | 3 | 2010 | 613 | 0.270 |
Why?
|
Treatment Outcome | 8 | 2024 | 1259 | 0.270 |
Why?
|
Longitudinal Studies | 3 | 2022 | 710 | 0.250 |
Why?
|
Young Adult | 6 | 2022 | 2427 | 0.250 |
Why?
|
Survival Rate | 4 | 2014 | 260 | 0.250 |
Why?
|
HIV Infections | 3 | 2017 | 694 | 0.250 |
Why?
|
Ethnic Groups | 2 | 2021 | 485 | 0.250 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2015 | 171 | 0.240 |
Why?
|
Receptor, ErbB-2 | 2 | 2016 | 46 | 0.240 |
Why?
|
Odds Ratio | 6 | 2017 | 671 | 0.240 |
Why?
|
Sensitivity and Specificity | 4 | 2020 | 304 | 0.240 |
Why?
|
Mitomycin | 1 | 2024 | 4 | 0.240 |
Why?
|
Isothiocyanates | 1 | 2024 | 8 | 0.240 |
Why?
|
BCG Vaccine | 1 | 2024 | 7 | 0.240 |
Why?
|
Logistic Models | 7 | 2013 | 926 | 0.220 |
Why?
|
Ultrasonography | 2 | 2020 | 35 | 0.220 |
Why?
|
Hyperpigmentation | 1 | 2003 | 1 | 0.220 |
Why?
|
Early Detection of Cancer | 3 | 2020 | 501 | 0.220 |
Why?
|
Colonoscopy | 1 | 2005 | 251 | 0.210 |
Why?
|
Lower Urinary Tract Symptoms | 2 | 2013 | 13 | 0.210 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2022 | 32 | 0.200 |
Why?
|
Breast | 1 | 2022 | 84 | 0.200 |
Why?
|
United States | 7 | 2015 | 3956 | 0.200 |
Why?
|
Hallucinogens | 1 | 2022 | 23 | 0.200 |
Why?
|
Hip Fractures | 2 | 2015 | 67 | 0.200 |
Why?
|
Arsenic Poisoning | 3 | 2007 | 3 | 0.200 |
Why?
|
Feasibility Studies | 2 | 2020 | 114 | 0.190 |
Why?
|
Sleep | 1 | 2021 | 58 | 0.190 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2015 | 70 | 0.190 |
Why?
|
Depressive Disorder, Major | 1 | 2022 | 124 | 0.190 |
Why?
|
Mammography | 3 | 2012 | 169 | 0.180 |
Why?
|
Cannabis | 1 | 2022 | 78 | 0.180 |
Why?
|
Erectile Dysfunction | 2 | 2011 | 24 | 0.180 |
Why?
|
Watchful Waiting | 1 | 2020 | 18 | 0.170 |
Why?
|
Wine | 2 | 2010 | 18 | 0.170 |
Why?
|
Carcinoma in Situ | 2 | 2009 | 17 | 0.170 |
Why?
|
Adolescent | 5 | 2017 | 3651 | 0.170 |
Why?
|
Survival Analysis | 2 | 2017 | 215 | 0.170 |
Why?
|
Pilot Projects | 1 | 2020 | 218 | 0.160 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2009 | 53 | 0.160 |
Why?
|
India | 7 | 2012 | 13 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 129 | 0.160 |
Why?
|
Receptors, Estrogen | 2 | 2016 | 51 | 0.160 |
Why?
|
Neoplasm Invasiveness | 5 | 2024 | 78 | 0.160 |
Why?
|
Vaccination | 1 | 2023 | 635 | 0.150 |
Why?
|
Disease-Free Survival | 2 | 2015 | 57 | 0.150 |
Why?
|
Cell Cycle Proteins | 2 | 2015 | 6 | 0.150 |
Why?
|
Apoptosis | 2 | 2015 | 10 | 0.150 |
Why?
|
Leuprolide | 1 | 2017 | 2 | 0.150 |
Why?
|
Goserelin | 1 | 2017 | 2 | 0.150 |
Why?
|
Imidazolidines | 1 | 2017 | 2 | 0.150 |
Why?
|
Flutamide | 1 | 2017 | 3 | 0.150 |
Why?
|
Anilides | 1 | 2017 | 3 | 0.150 |
Why?
|
Tosyl Compounds | 1 | 2017 | 3 | 0.150 |
Why?
|
Exercise | 1 | 2022 | 489 | 0.150 |
Why?
|
Diabetes Mellitus | 2 | 2014 | 487 | 0.150 |
Why?
|
Nitriles | 1 | 2017 | 7 | 0.150 |
Why?
|
Skin Diseases | 3 | 2005 | 10 | 0.150 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 59 | 0.150 |
Why?
|
Hospitalization | 1 | 2023 | 797 | 0.150 |
Why?
|
Clinical Laboratory Services | 1 | 2016 | 1 | 0.140 |
Why?
|
Time Factors | 6 | 2013 | 1086 | 0.140 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2021 | 531 | 0.140 |
Why?
|
Water Pollutants, Chemical | 2 | 2007 | 4 | 0.140 |
Why?
|
Medical Records | 2 | 2008 | 100 | 0.130 |
Why?
|
Administration, Oral | 1 | 2016 | 85 | 0.130 |
Why?
|
Disease Progression | 1 | 2017 | 264 | 0.130 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2015 | 15 | 0.130 |
Why?
|
Immunohistochemistry | 4 | 2017 | 44 | 0.130 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 4 | 0.130 |
Why?
|
Macrophages | 1 | 2015 | 4 | 0.130 |
Why?
|
Forecasting | 1 | 2016 | 75 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 5 | 0.130 |
Why?
|
Health Resources | 1 | 2015 | 37 | 0.130 |
Why?
|
Smoking | 3 | 2022 | 483 | 0.130 |
Why?
|
Nomograms | 1 | 2015 | 11 | 0.130 |
Why?
|
Estrogen Replacement Therapy | 1 | 2015 | 99 | 0.130 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 4 | 0.120 |
Why?
|
Lymphocyte Activation | 1 | 2015 | 7 | 0.120 |
Why?
|
SEER Program | 4 | 2017 | 91 | 0.120 |
Why?
|
Mastectomy, Segmental | 2 | 2012 | 20 | 0.120 |
Why?
|
European Continental Ancestry Group | 3 | 2012 | 529 | 0.120 |
Why?
|
Prevalence | 6 | 2014 | 884 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 3 | 0.110 |
Why?
|
Trans-Activators | 1 | 2013 | 8 | 0.110 |
Why?
|
Health Behavior | 2 | 2015 | 359 | 0.110 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 65 | 0.110 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 351 | 0.110 |
Why?
|
Men's Health | 2 | 2009 | 20 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 4 | 0.100 |
Why?
|
Life Style | 2 | 2012 | 332 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2015 | 129 | 0.100 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2012 | 18 | 0.100 |
Why?
|
Fractures, Bone | 1 | 2013 | 91 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 51 | 0.100 |
Why?
|
Clinical Trials as Topic | 1 | 2012 | 130 | 0.100 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2012 | 63 | 0.100 |
Why?
|
Asian Continental Ancestry Group | 1 | 2012 | 90 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2012 | 230 | 0.090 |
Why?
|
Health Status | 2 | 2009 | 298 | 0.090 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 8 | 0.090 |
Why?
|
Medical Audit | 1 | 2010 | 38 | 0.090 |
Why?
|
Prostatitis | 1 | 2010 | 5 | 0.090 |
Why?
|
Massachusetts | 1 | 2010 | 93 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2011 | 146 | 0.090 |
Why?
|
Sexually Transmitted Diseases | 1 | 2010 | 54 | 0.080 |
Why?
|
Family Characteristics | 1 | 2009 | 54 | 0.080 |
Why?
|
Confounding Factors (Epidemiology) | 1 | 2009 | 86 | 0.080 |
Why?
|
Educational Status | 1 | 2009 | 200 | 0.080 |
Why?
|
Bias | 1 | 2009 | 102 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3 | 0.080 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2008 | 7 | 0.080 |
Why?
|
Quality of Life | 1 | 2012 | 507 | 0.080 |
Why?
|
Body Height | 1 | 2008 | 62 | 0.080 |
Why?
|
Child | 3 | 2022 | 2474 | 0.080 |
Why?
|
Population Surveillance | 3 | 2016 | 263 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2009 | 211 | 0.080 |
Why?
|
Risk Assessment | 3 | 2020 | 1097 | 0.070 |
Why?
|
Residence Characteristics | 1 | 2009 | 248 | 0.070 |
Why?
|
Body Weight | 1 | 2008 | 219 | 0.070 |
Why?
|
Precancerous Conditions | 1 | 2007 | 47 | 0.070 |
Why?
|
Fetal Development | 1 | 2007 | 14 | 0.070 |
Why?
|
Cognition Disorders | 1 | 2007 | 31 | 0.070 |
Why?
|
Age Factors | 3 | 2015 | 917 | 0.070 |
Why?
|
Methionine | 1 | 2005 | 5 | 0.070 |
Why?
|
Selenium | 1 | 2005 | 4 | 0.070 |
Why?
|
Micronutrients | 1 | 2005 | 9 | 0.070 |
Why?
|
beta Carotene | 1 | 2005 | 17 | 0.070 |
Why?
|
Water | 1 | 2005 | 2 | 0.060 |
Why?
|
Respiration Disorders | 1 | 2005 | 5 | 0.060 |
Why?
|
Bronchiectasis | 1 | 2005 | 7 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 748 | 0.060 |
Why?
|
Surveys and Questionnaires | 4 | 2011 | 1309 | 0.060 |
Why?
|
Automation | 1 | 2005 | 24 | 0.060 |
Why?
|
Nutrition Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
Skin Pigmentation | 1 | 2004 | 6 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2024 | 7 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2024 | 15 | 0.060 |
Why?
|
Biopsy | 2 | 2017 | 74 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2015 | 6 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2015 | 29 | 0.060 |
Why?
|
Rural Population | 1 | 2003 | 51 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 9 | 0.050 |
Why?
|
Telomere | 1 | 2022 | 19 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 98 | 0.050 |
Why?
|
Diet | 1 | 2024 | 365 | 0.050 |
Why?
|
Tumor Burden | 2 | 2013 | 19 | 0.050 |
Why?
|
Ovary | 1 | 2020 | 3 | 0.050 |
Why?
|
BRCA2 Protein | 1 | 2020 | 5 | 0.050 |
Why?
|
BRCA1 Protein | 1 | 2020 | 6 | 0.050 |
Why?
|
Heterozygote | 1 | 2020 | 26 | 0.050 |
Why?
|
Mutation | 1 | 2020 | 128 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 23 | 0.040 |
Why?
|
ROC Curve | 1 | 2017 | 77 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2016 | 14 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2017 | 178 | 0.030 |
Why?
|
Biomarkers | 1 | 2017 | 301 | 0.030 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 3 | 0.030 |
Why?
|
Antigens, CD | 1 | 2015 | 5 | 0.030 |
Why?
|
Hysterectomy | 1 | 2015 | 29 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2009 | 454 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2015 | 13 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2016 | 381 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2015 | 155 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2015 | 3 | 0.030 |
Why?
|
Interferon Regulatory Factors | 1 | 2015 | 3 | 0.030 |
Why?
|
Protein Kinase C beta | 1 | 2015 | 3 | 0.030 |
Why?
|
Hyaluronan Receptors | 1 | 2015 | 4 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2015 | 5 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2015 | 8 | 0.030 |
Why?
|
Women's Health | 1 | 2015 | 200 | 0.030 |
Why?
|
Postmenopause | 1 | 2015 | 241 | 0.030 |
Why?
|
Orchiectomy | 1 | 2014 | 6 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 8 | 0.030 |
Why?
|
Michigan | 1 | 2014 | 26 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2014 | 13 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2015 | 238 | 0.030 |
Why?
|
Mortality | 1 | 2014 | 117 | 0.030 |
Why?
|
Transcriptional Regulator ERG | 1 | 2013 | 3 | 0.030 |
Why?
|
Cause of Death | 1 | 2014 | 181 | 0.030 |
Why?
|
Positive Regulatory Domain I-Binding Factor 1 | 1 | 2012 | 3 | 0.030 |
Why?
|
Ki-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
B7-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
LIM Domain Proteins | 1 | 2012 | 3 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2012 | 6 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2012 | 13 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2012 | 15 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 6 | 0.030 |
Why?
|
NF-kappa B | 1 | 2012 | 11 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
Patient Selection | 1 | 2012 | 190 | 0.020 |
Why?
|
Asian Americans | 1 | 2011 | 176 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2009 | 29 | 0.020 |
Why?
|
Acculturation | 1 | 2009 | 20 | 0.020 |
Why?
|
Mastectomy | 1 | 2009 | 36 | 0.020 |
Why?
|
Language | 1 | 2009 | 51 | 0.020 |
Why?
|
Hispanic Americans | 1 | 2011 | 404 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 145 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 77 | 0.020 |
Why?
|
Dutasteride | 1 | 2008 | 1 | 0.020 |
Why?
|
Azasteroids | 1 | 2008 | 1 | 0.020 |
Why?
|
Finasteride | 1 | 2008 | 1 | 0.020 |
Why?
|
African Continental Ancestry Group | 1 | 2009 | 162 | 0.020 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2008 | 9 | 0.020 |
Why?
|
Propensity Score | 1 | 2009 | 85 | 0.020 |
Why?
|
Recurrence | 1 | 2009 | 186 | 0.020 |
Why?
|
Prostatic Hyperplasia | 1 | 2008 | 24 | 0.020 |
Why?
|
African Americans | 1 | 2011 | 472 | 0.020 |
Why?
|
Health Services Research | 1 | 2009 | 231 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2008 | 50 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2008 | 237 | 0.020 |
Why?
|
Age Distribution | 1 | 2008 | 246 | 0.020 |
Why?
|
Intelligence Tests | 1 | 2007 | 4 | 0.020 |
Why?
|
Exanthema | 1 | 2007 | 7 | 0.020 |
Why?
|
Epidemiological Monitoring | 1 | 2007 | 25 | 0.020 |
Why?
|
Environmental Monitoring | 1 | 2007 | 26 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 50 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2005 | 32 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 154 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2008 | 368 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2007 | 160 | 0.020 |
Why?
|
Nutritional Status | 1 | 2004 | 30 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2005 | 205 | 0.010 |
Why?
|
Health Surveys | 1 | 2004 | 260 | 0.010 |
Why?
|
Child, Preschool | 1 | 2007 | 1409 | 0.010 |
Why?
|
Pregnancy | 1 | 2007 | 1494 | 0.010 |
Why?
|